Table.
Characteristics of included studies
| Author | Year | Design | No. | Age, years |
Male, % |
Indication, % CLIa |
Lesion location, % femoropoplitealb |
Intervention, % stentc |
Comparisond | Cointerventiond | Mean follow-up, months |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Soga | 2011 | Retrospective cohort | 618 | 72 ± 11 | 69% | 100% | 35% | 37% | No cilostazol | Aspirin, dopidogrel | 21 |
| Soga | 2012 | Retrospective cohort | 562 | 73 ± 9 | 76% | 26% | 100% | 100% | No cilostazol | Aspirin, clopidogrel | 25 |
| Ikushima | 2011 | Retrospective cohort | 28 | 76 ± 7 | 82% | 36% | 100% | 100% | Tidopidine | Aspirin | 18 |
| Iishi | 2010 | Retrospective cohort | 109 | 65 ± 11 | 64% | 21% | 100% | 65% | No cilostazol | Aspirin | 37 |
| Soga | 2009 | RCT | 78 | 71 ± 8 | 83% | 0% | 100% | 46% | No cilostazol | Aspirin, tidopidine | 24 |
| Iida | 2008 | RCT | 127 | 70 ± 8 | 72% | 25% | 100% | 87% | Tidopidine | Aspirin | 36 |
CLI, Critical limb ischemia; RCT, randomized controlled trial.
a
Indications included critical limb ischemia vs claudication.
b
Lesion locations include femoropopliteal and infrapoplitcal.
c
Interventions include stenting (with or without angioplasry) and angioplasty alone.
d
Aspirin dose, 81–200 mg/day; ticlopidine dose, 200 mg/day; clopidogrel dose, 75 mg/day.